CoChat

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration

Open access
Cervantes González, Alba, Irwin, David J., Alcolea, Daniel, McMillan, Corey T., Chen-Plotkin, Alice, Wolk, David, Sirisi, Sònia, Dols-Icardo, Oriol, Querol-Vilaseca, Marta, Illán-Gala, Ignacio, Santos-Santos, Miguel Angel, Fortea, Juan, Lee, Edward B., Trojanowski, John Q., Grossman, Murray, Lleó, Alberto, Belbin, Olivia · 2022 · Molecular Neurodegeneration

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background: Synapse degeneration is an early event in pathological frontotemporal lobar degeneration (FTLD). Consequently, a surrogate marker of synapse loss could be used to monitor early pathologic changes in patients with underlying FTLD. The aim of this study was to evaluate the relationship of antemortem cerebrospinal fluid (CSF) levels of 8 synaptic proteins with postmortem global tau and TDP-43 burden and cognitive performance and to assess their diagnostic capacity in a neuropathological FTLD cohort. Methods: We included patients with a neuropathological confirmation of FTLD-Tau (n = 24, mean age-at-CSF 67 years ± 11), FTLD-TDP (n = 25, 66 years ± 9) or AD (n = 25, 73 years ± 6) as well as cognitively normal controls (n = 35, 69 years ± 7) from the Penn FTD Center and ADRC. We used a semi-quantitative measure of tau and TDP-43 inclusions to quantify pathological burden across 16 brain regions. Statistical methods included Spearman rank correlations, one-way analysis of covariance, ordinal regression, step-wise multiple linear regression and receiver-operating characteristic curves. Result: CSF calsyntenin-1 and neurexin-2a were correlated in all patient groups (rs = .55 to .88). In FTLD-TDP, we observed low antemortem CSF levels of calsyntenin-1 and neurexin-2a compared to AD (.72-fold, p = .001, .77-fold, p = .04, respectively) and controls (.80-fold, p = .02, .78-fold, p = .02, respectively), which were inversely associated with post-mortem global TDP-43 burden (regression r2 = .56, p = .007 and r2 = .57, p = .006, respectively). A multimarker panel including calsyntenin-1 was associated with TDP-43 burden (r2 = .69, p = .003) and MMSE score (r2 = .19, p = .03) in FTLD. A second multimarker synaptic panel, also including calsyntenin-1, was associated with MMSE score in FTLD-tau (r2 = .49, p = .04) and improved diagnostic performance to discriminate FTLD-Tau and FTLD-TDP neuropathologic subtypes (AUC = .83). Conclusion: These synaptic panels have potential in the differential diagnosis of FTLD neuropathologic subtypes and as surrogate markers of cognitive performance in future clinical trials targeting TDP-43 or tau.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-022-00534-y

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pair-wise correlation of antemortem CSF levels of 8 synaptic proteins in FTLD, AD and controls. Pair-wise rs coefficients resulting from statistical tests performed in (a) FTLD-Tau, (b) FTLD-TDP, (c) AD and (d) controls are shown. Degree of shading is relative to size of Spearman rs coefficients, which are shown in bold where p < .05. A set of 3 proteins that correlated in all groups are highlighted by a black box
Fig. 1 Pair-wise correlation of antemortem CSF levels of 8 synaptic proteins in FTLD, AD and controls. Pair-wise rs coefficients resulting from statistical tests performed in (a) FTLD-Tau, (b) FTLD-TDP, (c) AD and (d) controls are shown. Degree of shading is relative to size of Spearman rs coefficients, which are shown in bold where p < .05. A set of 3 proteins that correlated in all groups are highlighted by a black boxCC BY · PubMed Central
Fig. 2 Antemortem CSF SRM intensities of the synaptic panel across patient groups. Violin plots show the distribution of SRM intensities for each synaptic protein quantified in CSF for patients with neuropathological confirmation of FTLD-Tau (Tau), FTLD-TDP (TDP) or AD and cognitively normal subjects (Control). Solid horizontal lines show the mean value for each and boxes represent the standard error of the mean. The horizontal dotted line represents the mean value in the control group for each protein. Summary statistics for ANCOVA including sex and age-at-CSF performed on square root transformed data are shown at the top of each plot. ANCOVA p-values are adjusted for multiple testing (9 proteins). *p < .05, **p < .01 for Dunnet’s post-hoc tests
Fig. 2 Antemortem CSF SRM intensities of the synaptic panel across patient groups. Violin plots show the distribution of SRM intensities for each synaptic protein quantified in CSF for patients with neuropathological confirmation of FTLD-Tau (Tau), FTLD-TDP (TDP) or AD and cognitively normal subjects (Control). Solid horizontal lines show the mean value for each and boxes represent the standard error of the mean. The horizontal dotted line represents the mean value in the control group for each protein. Summary statistics for ANCOVA including sex and age-at-CSF performed on square root transformed data are shown at the top of each plot. ANCOVA p-values are adjusted for multiple testing (9 proteins). *p < .05, **p < .01 for Dunnet’s post-hoc testsCC BY · PubMed Central
Fig. 3 Association of antemortem CSF levels of synaptic proteins with postmortem TDP-43 burden. Scatter plots show the antemortem SRM intensities for selected synaptic proteins quantified in CSF and post-mortem TDP-43 burden for patients with neuropathological confirmation of FTLD. Linear regression lines and standard error (shaded region) are shown for each plot. Adj.r2, p-values and t-statistics for the synaptic protein (syn t), time from CSF to autopsy (aut t), age-at-death (age t) and biological sex (sex t) are shown for each linear regression. P-values were adjusted for multiple testing (9 proteins)
Fig. 3 Association of antemortem CSF levels of synaptic proteins with postmortem TDP-43 burden. Scatter plots show the antemortem SRM intensities for selected synaptic proteins quantified in CSF and post-mortem TDP-43 burden for patients with neuropathological confirmation of FTLD. Linear regression lines and standard error (shaded region) are shown for each plot. Adj.r2, p-values and t-statistics for the synaptic protein (syn t), time from CSF to autopsy (aut t), age-at-death (age t) and biological sex (sex t) are shown for each linear regression. P-values were adjusted for multiple testing (9 proteins)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 19

Metadata

Authors
Cervantes González, A., Irwin, D. J., Alcolea, D., McMillan, C. T., Chen-Plotkin, A., Wolk, D., Sirisi, S., Dols-Icardo, O., Querol-Vilaseca, M., Illán-Gala, I., Santos-Santos, M. A., Fortea, J., Lee, E. B., Trojanowski, J. Q., Grossman, M., Lleó, A., & Belbin, O.
Affiliations
  • University of Pennsylvania (US)
  • Universitat Autònoma de Barcelona (ES)
Corresponding author
Belbin, Olivia
Venue
Molecular Neurodegeneration
Published
2022-04-08
Volume
17
Issue
1
Pages
29-29
ISSN
1750-1326 (ISSN-L)
OpenAlex
W4223617068
Cited by
19
References
29
Citations by year
2026: 1 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 3
FWCI
2.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Instituto de Salud Carlos III (PI18/00327, PI20/01330, PI20/01473, C18/00011)
  • Centro de Investigación Biomédica en Red-Enfermedades Neurodegenerativas (Programa 1)
  • Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR PROD 2019 00088, SLT002/16/00408)
  • National Institute on Aging (P01AG066597, P30AG072979, U19 AG062418, 1R01AG056850-01A1, R21AG056974, R01AG061566)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
frontotemporal lobar degeneration, TDP-43 pathology, cerebrospinal fluid biomarkers, synaptic proteins, FTLD-tau, FTLD-TDP, Alzheimer's disease, tau pathology, multimarker panels, cognitive performance, synaptic degeneration, diagnostic accuracy, amyloid-beta, neurofibrillary tangles, neuroinflammation, neurodegeneration
MeSH terms
Aged, Cognition, DNA-Binding Proteins, Humans, Middle Aged, Biomarkers, tau Proteins, Frontotemporal Lobar Degeneration, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. https://app.cochat.ai/papers/10.1186/s13024-022-00534-y
The paper
Cervantes González, A., Irwin, D. J., Alcolea, D., McMillan, C. T., Chen-Plotkin, A., Wolk, D., Sirisi, S., Dols-Icardo, O., Querol-Vilaseca, M., Illán-Gala, I., Santos-Santos, M. A., Fortea, J., Lee, E. B., Trojanowski, J. Q., Grossman, M., Lleó, A., & Belbin, O. (2022). Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-022-00534-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.